Delivery Order SPE2DR25D3010-SPE2DR26F88ET
- Not listed
- The Defense Logistics Agency awarded a $4,156.56 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Orgovyx 120 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and represents a non-set-aside, competitively awarded contract. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Orgovyx 120 mg tablets in quantities of 30 units, with a ceiling value of $1,460.13 and a firm fixed price contract type. This award is non-competitive and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $4,380.39 delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Orgovyx 120 mg tablets (30-count units). This non-set-aside, competitively awarded contract reflects a firm fixed-price arrangement with performance to be completed by December 9, 2025, at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,385.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Orgovyx 120 mg tablets in quantities of 30 units. This is a non-set-aside contract with an ultimate completion date of December 1, 2025, and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $4,156.56 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Orgovyx 120 mg tablets (30-count unit dose packaging). The contract is categorized as a non-set-aside competitive award with an ultimate completion date of October 7, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a Delivery Order contract to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Orgovyx 120 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $4,156.56 and an ultimate completion date of May 15, 2025. The contract represents a non-competitive set-aside and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,760.78 to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Orgovyx 120 mg tablets in quantities of 30 units. This firm fixed-price delivery order, with an ultimate completion date of December 26, 2025, represents a non-set-aside competitive award to support federal medical procurement needs. The contract is executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $4,156.56 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of Orgovyx 120 mg tablets in quantities of 30 units. This is a non-set-aside contract with an ultimate completion date of June 26, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $2,920.26 to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Orgovyx 120 mg tablets (30-count units). This non-competitive delivery order represents a firm fixed-price transaction with a completion deadline of December 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $4,156.56 to AmerisourceBergen Drug Corp for the supply of Orgovyx 120 mg tablets (30-count units) on August 5, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- SPE2DR25D3010Indefinite Delivery Contract
- SPE2DR25D3010-SPE2DR26F88ETDelivery Order
The Defense Logistics Agency awarded a $4,380.39 firm fixed price delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Orgovyx 120 mg tablets (30-count units). This is a non-competitive, non-set-aside award with performance completion targeted for December 31, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, maintains an extensive portfolio of federal medical supply contracts predominantly with the Defense Logistics Agency and its Medical Supply Chain. The company's federal awards demonstrate capability across diverse pharmaceutical categories including specialty medications, vaccines, and medical devices supporting military and veteran healthcare systems. This award for Orgovyx, a hormone therapy medication, exemplifies the company's role as a primary source for pharmaceutical commodities across multiple therapeutic domains in support of Department of Defense medical requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 12/8/25 |